European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) [Yahoo! Finance]
CSL LTD SP/ADR (CSLLY)
NASDAQ:AMEX Investor Relations:
csl.com/investors
Company Research
Source: Yahoo! Finance
Thu, February 13, 2025 at 1:00 PM GMT+1 6 min read In This Article CMXHF CSLLY - ANDEMBRY ® , the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body - ANDEMBRY reinforces CSL's decades-long commitment to delivering innovative treatment modalities to the HAE community and comes with a convenient patient-centric pre-filled pen (auto-injector) enabling subcutaneous self-injection - Supported by the Phase 3 VANGUARD trial, this marks the third regulatory approval for ANDEMBRY, which was also recently approved by Australia's Therapeutic Goods Administration (TGA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in January MARBURG, Germany Feb. 13, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved
Show less
Read more
Impact Snapshot
Event Time:
CSLLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSLLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSLLY alerts
High impacting CSL LTD SP/ADR news events
Weekly update
A roundup of the hottest topics
CSLLY
News
- Heavenly Garage Doors & Gates Announces Expand Mobile Service Network To Support Rising Demand for Garage Door, Gate, and Fence Repairs Across Los Angeles [Yahoo! Finance]Yahoo! Finance
- Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five YearsPR Newswire
- LA County contractor accused of defrauding families in home remodeling projects [CBS News]CBS News
- CSL (OTCMKTS:CSLLY) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- CSL to pump $1.5bn into US plasma supply chain [Yahoo! Finance]Yahoo! Finance